Skip to main content

Market Overview

Sorrento Therapeutics Starts Large Efficacy Trial For Intranasal COVID-19 Antibody In UK

Share:
Sorrento Therapeutics Starts Large Efficacy Trial For Intranasal COVID-19 Antibody In UK
  • The U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) signed off Sorrento Therapeutics Inc's (NASDAQ: SRNE) Phase 2 trial evaluating COVI-DROPS in newly diagnosed COVID-19 infected patients.
  • The application was submitted as a rolling application, and the MHRA cleared the study in less than a month from Sorrento's first submission to the MHRA.
  • The application was supported by the safety data from a healthy subject study completed in the U.S., which showed a safety profile comparable to placebo with doses up to 60 mg.
  • No serious adverse effects or dose-limiting toxicities were reported, and all adverse effects were mild in severity.
  • The maximum tolerated dose was not reached.
  • The efficacy trial is a large double-blind clinical trial enrolling 350 outpatients with COVID-19 who are asymptomatic or have mild symptoms.
  • The trial will complement the Phase 2 trial currently being started in the U.S. and a separate trial starting in Mexico.
  • COVI-DROPS is administered as an intranasal instillation in each nares and utilizes the same neutralizing antibody drug substance as COVI-AMG, the intravenous formulation.
  • The antibody is active against the original SARS-CoV-2 virus and the most prevalent viral variants of concern.
  • The results of this Phase 2 trial in the U.K. will be combined with the results of the U.S. and Mexico Phase 2 trials.
  • Price Action: SRNE shares are up 6.99% at $9.49 in the premarket session on the last check Monday.
 

Related Articles (SRNE)

View Comments and Join the Discussion!

Posted-In: Biotech Long Ideas News Health Care FDA Movers Trading Ideas General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com